These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 27562865)

  • 1. MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.
    Erdmann K; Kaulke K; Rieger C; Salomo K; Wirth MP; Fuessel S
    J Cancer Res Clin Oncol; 2016 Nov; 142(11):2249-61. PubMed ID: 27562865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
    Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
    Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
    Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
    J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-144 Suppresses Prostate Cancer Growth and Metastasis by Targeting EZH2.
    Sun XB; Chen YW; Yao QS; Chen XH; He M; Chen CB; Yang Y; Gong XX; Huang L
    Technol Cancer Res Treat; 2021; 20():1533033821989817. PubMed ID: 33550923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
    Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
    Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a.
    Uchiyama N; Tanaka Y; Kawamoto T
    Eur J Pharmacol; 2017 Oct; 812():138-146. PubMed ID: 28705714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.
    Dang X; Ma A; Yang L; Hu H; Zhu B; Shang D; Chen T; Luo Y
    Cancer Genet; 2012 Mar; 205(3):113-23. PubMed ID: 22469510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long Noncoding RNA DLX6-AS1 Regulates the Growth and Aggressiveness of Colorectal Cancer Cells Via Mediating the miR-26a/EZH2 Axis.
    Kong WQ; Liang JJ; Du J; Ye ZX; Gao P; Liang YL
    Cancer Biother Radiopharm; 2021 Nov; 36(9):753-764. PubMed ID: 32379493
    [No Abstract]   [Full Text] [Related]  

  • 9. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.
    Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G
    Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.
    Lu J; He ML; Wang L; Chen Y; Liu X; Dong Q; Chen YC; Peng Y; Yao KT; Kung HF; Li XP
    Cancer Res; 2011 Jan; 71(1):225-33. PubMed ID: 21199804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-26a promoted by interferon-alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2.
    Wang G; Sun Y; He Y; Ji C; Hu B; Sun Y
    Genet Test Mol Biomarkers; 2015 Jan; 19(1):30-6. PubMed ID: 25494962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
    Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY
    J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2.
    Pan MZ; Song YL; Gao F
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8795-8805. PubMed ID: 31696466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-26a-5p restoration
    Zhang W; Nie Q; Zhang X; Huang L; Pang G; Chu J; Yuan X
    Expert Opin Ther Targets; 2023; 27(12):1285-1297. PubMed ID: 38155599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA MINCR promotes gallbladder cancer progression through stimulating EZH2 expression.
    Wang SH; Yang Y; Wu XC; Zhang MD; Weng MZ; Zhou D; Wang JD; Quan ZW
    Cancer Lett; 2016 Sep; 380(1):122-33. PubMed ID: 27345740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
    Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
    Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
    Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
    Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development.
    Tao T; Liu D; Liu C; Xu B; Chen S; Yin Y; Ang L; Huang Y; Zhang X; Chen M
    Biochim Biophys Acta; 2014 Sep; 1839(9):858-65. PubMed ID: 25017995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.